# Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

> **NCT02804815** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 11000 (estimated)

## Conditions studied

- Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Gastro-oesophageal Cancer

## Interventions

- **DRUG:** Aspirin 100mg
- **DRUG:** Aspirin 300mg
- **DRUG:** Placebo 100mg
- **DRUG:** Placebo 300mg

## Key facts

- **NCT ID:** NCT02804815
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 11000 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02804815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02804815, "Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02804815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*